Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Nifedpine in Compounded Oral and Topical Preparations

Author(s):  McCluskey Susan V, Brunn Gregory J

Issue:  Mar/Apr 2011 - Volume 15, Number 2
View All Articles in Issue

Abstract:  The purpose of this study was to evaluate nifedipine oral and topical compounding formulas and procedures. Topical preparations were compounded in Plastibase 50 W, using combinations of two drug sources and four types of light exposure. Oral preparations were compounded using combinations of two drug sources, two types of light exposure, and four suspending vehicles. Drug sources consisted of the contents of commercial nifedipine soft-gelatin capsules and nifedipine powder USP. Light exposures were ambient, red-shaded, goldshaded fluorescent light, or a combination of ambient and gold-shaded fluorescent light. Topical formulations were assessed for potency, uniformity, and usability characteristics such as acceptable look and feel of the preparation. Oral formulations were assessed for potency, uniformity, and usability characteristics, such as acceptable look and taste of the preparation. Preparations which were compounded, in entirety, under gold-shaded fluorescent light with nifedipine powder USP as the drug source resulted in a potency of 90% to 110% of intended value. Preparations that were exposed to ambient or red-shaded fluorescent light at any time in the compounding procedure resulted in subpotent preparations. Nifedipine is sensitive to certain wavelengths of light resulting in rapid degradation. When exposed to fluorescent room light, significant degradation may occur in a time frame less than what may be required to compound a preparation, necessitating the need for compounding to take place under a spectrum of light that will not degrade the drug. Gold fluorescent lighting appears to prevent nifedipine degradation during compounding procedures. Concerning the drug source, the use of commercial nifedipine soft gelatin capsules was problematic, while nifedipine powder USP is a suitable choice for the active pharmaceutical ingredient.

Related Keywords: Susan V. McCluskey, RPh, BS Pharm, Gregory J. Brunn, PharmD, PhD, nifedipine, calcium channel blocker, hypertension, high blood pressure, angina, photodegradation, degradation, light exposure, potency, stability, topical preparations, oral preparations, light sensitivity, vehicle


Printer-Friendly Version

Download in electronic PDF format for $55

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Nifedpine in Compounded Oral and Topical Preparations McCluskey Susan V, Brunn Gregory J Mar/Apr 2011 166-169 Buy
Quality Control: Photostability of Compounded Preparations Allen Loyd V Jr May/Jun 2020 200-205 Buy
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases Teimouri Arezou, Yeung Pollen, Agu Remigius U Jul/Aug 2021 344-351 Buy
Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing Teimouri Arezou, Yeung Pollen, Agu Remigius U Nov/Dec 2020 501-508 Buy
Verapmail Hydrochloride 50 mg/mL in SyrSpend SF Allen Loyd V Jr Nov/Dec 2019 494 Buy
Stability of Nitroglyercin 100 mcg/mL Stored in Polypropylene Syringes McCluskey Susan V, Vu Nicole, Rueter John Nov/Dec 2013 515-519 Buy
Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes Kirkham Kylian, Munson Jessica M, McCluskey Susan V, Graner Kevin K Sep/Oct 2017 426-429 Buy
Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure Ip Kendice, Banov Daniel, Bassani Gus, Morgan Latisha Mar/Apr 2019 167-175 Buy
Nifedipine 1-mg/500-mg Oral Powder Allen Loyd V Jr Sep/Oct 2011 422 Buy
Nifedipine 10-mg/mL Oral Suspension Allen Loyd V Jr Sep/Oct 2011 423 Buy